Alzheimer's disease
Authors
Discussion
Loading...
Member takes
Implication
Review outlines disease mechanisms and protracted preclinical stages in Alzheimer's disease, highlighting opportunities to shift from symptomatic treatment toward early prevention.
Key Points
- To provide an updated overview of the epidemiology, genetics, pathology, and clinical presentation of Alzheimer's disease, while evaluating how insights into preclinical pathogenesis can inform prevention-oriented therapies.
- Narrative synthesis of current evidence regarding the genetic, pathological, and epidemiological features of Alzheimer's disease.
- Review of clinical diagnostic presentations, standard symptomatic therapies, and emerging translational targets directed at early preclinical stages.
- Alzheimer's disease remains the primary contributor to global dementia, driven by complex genetic and pathological cascades.
- Identification of an extended, asymptomatic preclinical phase provides a crucial therapeutic window to transition from reactive symptom management to targeted primary and secondary prevention.
Cite This Study
Lane et al. (2017) studied this question.